Custom cancer vaccine aims to stop myeloma before it starts
NCT ID NCT03631043
Summary
This early-stage study tested a personalized vaccine designed to prevent smoldering multiple myeloma from turning into active cancer. Doctors created a custom vaccine from each patient's own blood and bone marrow cells to train their immune system to attack cancer cells. The main goals were to see if making this vaccine was possible and to check its safety in 30 patients at high risk of their condition worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.